TPST vs. HOOK, JAGX, RLYB, SCYX, MRNS, IFRX, ASMB, VTVT, MNOV, and DERM
Should you be buying Tempest Therapeutics stock or one of its competitors? The main competitors of Tempest Therapeutics include Hookipa Pharma (HOOK), Jaguar Health (JAGX), Rallybio (RLYB), SCYNEXIS (SCYX), Marinus Pharmaceuticals (MRNS), InflaRx (IFRX), Assembly Biosciences (ASMB), vTv Therapeutics (VTVT), MediciNova (MNOV), and Journey Medical (DERM). These companies are all part of the "pharmaceutical preparations" industry.
Hookipa Pharma (NASDAQ:HOOK) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, community ranking, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.
Tempest Therapeutics has a net margin of 0.00% compared to Tempest Therapeutics' net margin of -88.73%. Tempest Therapeutics' return on equity of -33.33% beat Hookipa Pharma's return on equity.
Tempest Therapeutics received 8 more outperform votes than Hookipa Pharma when rated by MarketBeat users. However, 69.11% of users gave Hookipa Pharma an outperform vote while only 64.14% of users gave Tempest Therapeutics an outperform vote.
Tempest Therapeutics has lower revenue, but higher earnings than Hookipa Pharma. Tempest Therapeutics is trading at a lower price-to-earnings ratio than Hookipa Pharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Hookipa Pharma had 3 more articles in the media than Tempest Therapeutics. MarketBeat recorded 3 mentions for Hookipa Pharma and 0 mentions for Tempest Therapeutics. Hookipa Pharma's average media sentiment score of 0.97 beat Tempest Therapeutics' score of 0.74 indicating that Tempest Therapeutics is being referred to more favorably in the news media.
63.9% of Hookipa Pharma shares are held by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are held by institutional investors. 5.8% of Hookipa Pharma shares are held by company insiders. Comparatively, 3.3% of Tempest Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Hookipa Pharma has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, Tempest Therapeutics has a beta of -1.65, meaning that its stock price is 265% less volatile than the S&P 500.
Hookipa Pharma currently has a consensus target price of $4.67, indicating a potential upside of 472.32%. Tempest Therapeutics has a consensus target price of $25.00, indicating a potential upside of 686.16%. Given Hookipa Pharma's higher probable upside, analysts clearly believe Tempest Therapeutics is more favorable than Hookipa Pharma.
Summary
Hookipa Pharma beats Tempest Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Tempest Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TPST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tempest Therapeutics Competitors List
Related Companies and Tools
